Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IONIS PTP1BRx
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral (subcutaneous Or Intravenous Injection)
01
Overview
IONIS PTP1BRx (ISIS 404173) is an antisense oligonucleotide drug developed to inhibit the expression of protein tyrosine phosphatase non-receptor type 1 (PTP-1B), a negative regulator of insulin signaling. By targeting and reducing PTP-1B mRNA, the drug aims to improve insulin sensitivity and glycemic control in patients with type 2 diabetes mellitus. It has demonstrated antidiabetic activity in preclinical and clinical studies, particularly for patients with obesity-related insulin resistance. The compound was developed by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) and reached phase II clinical trials for type 2 diabetes mellitus[1][3][4][9].
- Other names
- Antisense PTP-1B gene therapy
02
Targets
PTPN1 (Protein tyrosine phosphatase 1B)
Beyond the preview
Go deeper on IONIS PTP1BRx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IONIS PTP1BRx.